N. S. Ujagar, S. Poudel, S. Saraswat, S. Sureshchandra, J. Kim, U.-V. Le, A. R. Jones, N. Hopkins, T. Sriram, M. Matson, E. H. Pilier, M. Mejia, S. S. Bailin, C. N. Wanjalla, M. Y. Sy, D. C. Newcomb, C. Walsh, L. E. Wagar, B. S. Nikolajczyk, X. D. Zhang, D. R. Green, D. A. Nicholas
Based on in vitro and animal studies, Th17 cells are classified as pathogenic (pTh17) or non-pathogenic (nTh17), but the inability to identify these subsets in primary human samples limits translation. We developed a single-cell ELISA to enrich human Th17s, enabling transcriptomic and flow-cytometric classification. nTh17 cells predominated in Type 2 diabetes and exhibited signatures of acylcarnitine synthesis, while knockdown of CPT1A demonstrated that acylcarnitine metabolism regulates Th17 pathogenicity.